Deutsche Bank began coverage on shares of Diplomat Pharmacy (NYSE:DPLO) in a research report report published on Thursday morning, BenzingaRatingsTable reports. The firm issued a sell rating and a $4.00 price target on the stock.
Other equities analysts also recently issued research reports about the company. Wells Fargo & Co upped their price target on Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a market perform rating in a research report on Tuesday, August 13th. Zacks Investment Research cut Diplomat Pharmacy from a hold rating to a sell rating in a research note on Wednesday, August 14th. Barclays set a $7.00 price objective on Diplomat Pharmacy and gave the stock a buy rating in a research note on Friday, August 9th. Finally, ValuEngine upgraded Diplomat Pharmacy from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $9.43.
Shares of DPLO opened at $5.65 on Thursday. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.66 and a current ratio of 0.99. The stock has a 50 day simple moving average of $5.60 and a 200 day simple moving average of $5.55. Diplomat Pharmacy has a 52-week low of $4.17 and a 52-week high of $21.48. The firm has a market capitalization of $454.22 million, a PE ratio of 28.25 and a beta of 1.01.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). Diplomat Pharmacy had a negative net margin of 8.93% and a negative return on equity of 4.01%. The business had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.23 billion. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. Diplomat Pharmacy’s revenue for the quarter was down 9.1% compared to the same quarter last year. Equities research analysts predict that Diplomat Pharmacy will post -0.81 EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in the company. Aperio Group LLC raised its stake in Diplomat Pharmacy by 127.0% in the 2nd quarter. Aperio Group LLC now owns 28,304 shares of the company’s stock valued at $172,000 after acquiring an additional 15,834 shares during the period. JPMorgan Chase & Co. raised its stake in Diplomat Pharmacy by 390.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,445,834 shares of the company’s stock valued at $8,632,000 after acquiring an additional 1,150,740 shares during the period. Laurion Capital Management LP bought a new stake in Diplomat Pharmacy in the 1st quarter valued at $710,000. Dimensional Fund Advisors LP raised its stake in Diplomat Pharmacy by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,128,358 shares of the company’s stock valued at $28,650,000 after acquiring an additional 395,246 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in Diplomat Pharmacy by 446.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 13,104 shares of the company’s stock valued at $76,000 after acquiring an additional 10,708 shares during the period. Institutional investors own 84.58% of the company’s stock.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: Why are percentage gainers important?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.